期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

GABRA5基因启动子-754C／T多态性与耐药性癫痫的相关性分析

Association between the polymorphisms of GABRA5 gene promoter 754C/T and drug-- resistant epilepsy
原文传递
导出
摘要 目的探讨GABRA5基因启动子-754C／T突变和癫痫耐药的相关性。方法收集125例诊断明确、治疗合理的汉族癫痫患者。根据是否符合DRE（耐药性癫痫）诊断标准将其分为耐药组（63例）和非耐药组（62例）。采用聚合酶链反应限制性片段长度多态性方法检测患者外周血GABRA5基因启动子-754c／T多态性。结果耐药组CC、CT、TT基因型分别占23．8％、41．2％、35．0％，非耐药组分别占16．1％、50．0％、33．9％，总体差异无统计学意义（x^2=1．454，P=0．483）。耐药组等位基因C、T频率分别为44．4％、55．6％，非耐药组患者分别为41．1％、58．9％，差异也无统计学意义（x^2=0．281，P=0．596）。结论本研究未发现GABRA5基因启动子-754C／T多态性与汉族DRE有关。
作者 许春燕 许志恩
机构地区 广东医学院附属医院神经内科
出处 《神经疾病与精神卫生》 2013年第1期69-71,共3页 Journal of Neuroscience and Mental Health
关键词 耐药性癫痫 基因 多态性 GABRA5基因 限制性片段长度 Drug--resistant epilepsy Gene Polymorphism GABRA5 gene Restriction fragment length
分类号 R681 [医药卫生—骨科学]
  • 相关文献

参考文献11

  • 1Schmidt D, Loscher W. New developments in antiepileptic drug resistance: an integrative view[J]. Epilepsy Curr, 2009, 9(2) :47-52.
  • 2Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs[J]. Nature Reviews Neuroscience, 2004,5 (7) : 553 - 564.
  • 3Arion D,Sabatini M ,Unger T, et al. Correlation of transcrip- tome profile with electrical activity in temporal lobe epilepsy [J]. Neurobiol Dis,2006,22(2):374-387.
  • 4Bethmann K, Fritschy JM, Brandt C, et al. Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epi- lepsy[J]. Neurobiol Dis, 2008,31 (2) : 169.
  • 5洪桢,洪震,周东.耐药性癫痫的定义：国际抗癫痫联盟治疗策略委员会专项工作组统一提案[J].中华神经科杂志,2010,43(7):487-492. 被引量：21
  • 6王秀坤,Nielsen M.GABA_A受体药理学研究进展[J].国外医学（药学分册）,2001,28(1):29-34. 被引量：17
  • 7Brooks-Kayal AR, Shumate MD, Jin H, et al. Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy[J]. Nature Medicine, 1998,4(10) :1 166-1 172.
  • 8Mariotti V, Melissari E, Amar S. Effect of prolonged pheny- toin administration on rat brain gene expression assessed by DNA microarrays[J]. Exp Biol Med(Maywood), 2010,235 (3) :300-310.
  • 9Almgren M, Nyengaard JR, Persson B, et al. Carbamazepine protects against neuronal hyperplasia and abnormal gene ex- pression in the megeneephaly mouse[J]. Neurobiol Dis,2008, 32(3) :364-376.
  • 10Atack JR,Bayley PJ, Fletcher SR, et al. The proconvulsant effects of the GABA A a5 subtype-selective compound RY- 080 may not be a5- mediated[J]. Eur J Pharmacol, 2006,548 (1/3) :77-82.

二级参考文献40

  • 1Perucca E.Pharmacoresistance in epilepsy.How should it be defined? CNS Drugs,1998,10:171-179.
  • 2Tanganelli P,Regesta G.Clinical aspects and biological bases of drug-resistant epilepsy.Epilepsy Res,1999,34:109-122.
  • 3Berg AT,Vickrey BG,Testa FM,et al.How long does it take for epilepsy to become intractable? A prospective investigation.Ann Neurol,2006,60:73-79.
  • 4Kwan P,Brodie MJ.Issues of medical intractability for surgicalcandidacy//Wyllie E.The treatment of epilepsy:principles and Practice.4th ed.Philadelphia:Lippincott Williams & Wilkins,2006:983-991.
  • 5Arzimanoglou A,Ryvlin P.Towards a clinically meaningful definition of drug-resistance//Kahane P,Berg A,L(o)scher W,et al.Progress in Epileptic Disorder.Vol.7.Drug-resiatant eplilepsies.Montrouge:John Libbey Eurotext,2008:1-6.
  • 6Kahane P,Berg A,L(o)scher W,et al.Drug-resistant Epilepsies.Progress in Epileptic Disorders.Vol.7.Montrouge:John Libbey Eurotext,2008.
  • 7World Health Organization.Collaborating Centre for Drug Statistics Methodology.About the ATC/DDD system.Accessed December 1,2008 at http://www.whocc.no/atcddd/.
  • 8Perucca E,Dulac O,Shorvon S,et al.Harnessing the clinical potential of antiepileptic drug therapy:dosage optimisation.CNS Drugs,2001,15:609-621.
  • 9Sillanp(a)(a) M,Haataja L,Shinnar S.Perceived impact of childhood-onset epilepsy on quality of life as an adult.Epitepsia,2004,45:971-977.
  • 10Vickrey BG,Hays RD,Bausch R,et al.Outcomes in 248 patients who had diagnostic evaluations for epilepsy surgery.Lancet,1995,346:1445-1449.

共引文献36

神经疾病与精神卫生
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部